Peringatan Keamanan

Some reports have shown adverse effects when used in therapeutical doses and some teratogenic effects have been demonstrated when used in large doses. The current LD50 reported in rats is 10700 mg/kg.T121

Dextran

DB09255

small molecule approved investigational vet_approved

Deskripsi

Dextran is a polysaccharide that differs from others in that its glucose units are joined together 1:6 glucoside links. The main chain of glucose has short branches at frequent intervals which are probably joined by 1:3 and 1:4 glucoside links. The chains can be composed of about 200,000 glucose units.A32011 Many bacteria, like Leuconostoc, can synthesize dextran from sucrose, and this activity is used commercially to obtain dextran.T121

Dextran 40 is a sterile, nonpyrogenic preparation of low molecular weight dextran (average mol. wt. 40,000) in 5% Dextrose Injection or 0.9% Sodium Chloride Injection. It is administered by intravenous infusion.

Dextran 75 is a complex branched glucan with an average molecular weight 75000 Daltons. It is produced from certain bacteria that with ?-1,6 glycosidic linkages between glucose molecules and ?-1,3 linkages between branches. When labelled with technetium Tc99m, dextran 75 is intravenously administered as an imaging agent to detect and diagnose conditions in the vascular compartment such as pericardial effusion or ventricular aneurysm.

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) The elimination half-life will depend on the length of the carbohydrate chain. The higher the molecular weight of the dextran the longer it will be the elimination half-life. The half-life will go from 1.9 hours from dextran 1 to 42 hours in the case of dextran 60.[T120, T121]
Volume Distribusi The reported volume of distribution of dextran suggested a distribution throughout the blood volume. This volume of distribution is reported to be of around 120 ml. The organ that presented a higher accumulation of dextran was the liver.[L1464]
Klirens (Clearance) -

Absorpsi

Dextran presents a very low oral bioavailability that is reduced as the chain gets longer. Thus, the bioavailability of dextran is inversely proportional to the length of the carbohydrate chain.T121

Metabolisme

Long chains of dextran such as dextran 60 are highly metabolized in the liver until formation of lower molecular weight products before being excreted from the body.T121

Rute Eliminasi

The elimination of dextran will depend on the length of the carbohydrate chain, the administration route, and the molecular weight. For dextran 1, it is reported to be mainly secreted unchanged in the urine in a ratio of 80% of the administered dose when administered parentally. It is registered that the weight threshold for unrestricted glomerular filtration is about 15 kDa and if the dextran overpasses 50 kDa it will not be renally eliminated in any significant amount.T121

Interaksi Makanan

1 Data
  • 1. Avoid herbs and supplements with anticoagulant/antiplatelet activity. Dextran has antithrombotic activity, which may increase the bleeding risk if combined with antiplatelet/anticoagulant herbs. Examples include garlic, ginger, bilberry, danshen, piracetam, and ginkgo biloba.

Interaksi Obat

1130 Data
Apixaban Apixaban may increase the anticoagulant activities of Dextran.
Dabigatran etexilate Dabigatran etexilate may increase the anticoagulant activities of Dextran.
Dasatinib The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Dextran.
Deferasirox The risk or severity of gastrointestinal bleeding can be increased when Dextran is combined with Deferasirox.
Ursodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Dextran is combined with Ursodeoxycholic acid.
Glycochenodeoxycholic Acid The risk or severity of bleeding and bruising can be increased when Dextran is combined with Glycochenodeoxycholic Acid.
Cholic Acid The risk or severity of bleeding and bruising can be increased when Dextran is combined with Cholic Acid.
Glycocholic acid The risk or severity of bleeding and bruising can be increased when Dextran is combined with Glycocholic acid.
Deoxycholic acid The risk or severity of bleeding and bruising can be increased when Dextran is combined with Deoxycholic acid.
Taurocholic acid The risk or severity of bleeding and bruising can be increased when Dextran is combined with Taurocholic acid.
Obeticholic acid The risk or severity of bleeding and bruising can be increased when Dextran is combined with Obeticholic acid.
Chenodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Dextran is combined with Chenodeoxycholic acid.
Taurochenodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Dextran is combined with Taurochenodeoxycholic acid.
Tauroursodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Dextran is combined with Tauroursodeoxycholic acid.
Bamet-UD2 The risk or severity of bleeding and bruising can be increased when Dextran is combined with Bamet-UD2.
Dehydrocholic acid The risk or severity of bleeding and bruising can be increased when Dextran is combined with Dehydrocholic acid.
Hyodeoxycholic Acid The risk or severity of bleeding and bruising can be increased when Dextran is combined with Hyodeoxycholic Acid.
Edoxaban The risk or severity of bleeding can be increased when Edoxaban is combined with Dextran.
Ibrutinib The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Dextran.
Obinutuzumab The risk or severity of bleeding and hemorrhage can be increased when Dextran is combined with Obinutuzumab.
Rivaroxaban Dextran may increase the anticoagulant activities of Rivaroxaban.
Sugammadex The risk or severity of bleeding and hemorrhage can be increased when Dextran is combined with Sugammadex.
Tibolone Tibolone may increase the anticoagulant activities of Dextran.
Tipranavir The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Dextran.
Urokinase Urokinase may increase the anticoagulant activities of Dextran.
Vitamin E Vitamin E may increase the anticoagulant activities of Dextran.
Vorapaxar The risk or severity of bleeding and hemorrhage can be increased when Vorapaxar is combined with Dextran.
Ginkgo biloba Ginkgo biloba may increase the anticoagulant activities of Dextran.
Ifosfamide The risk or severity of bleeding can be increased when Ifosfamide is combined with Dextran.
Quinine The therapeutic efficacy of Dextran can be increased when used in combination with Quinine.
Quinidine The therapeutic efficacy of Dextran can be increased when used in combination with Quinidine.
Tamoxifen The risk or severity of bleeding can be increased when Tamoxifen is combined with Dextran.
Toremifene The risk or severity of bleeding can be increased when Toremifene is combined with Dextran.
Pentoxifylline The therapeutic efficacy of Dextran can be increased when used in combination with Pentoxifylline.
Pentosan polysulfate Pentosan polysulfate may increase the anticoagulant activities of Dextran.
Levocarnitine The therapeutic efficacy of Dextran can be increased when used in combination with Levocarnitine.
Abciximab Dextran may increase the anticoagulant activities of Abciximab.
Diethylstilbestrol Diethylstilbestrol may decrease the anticoagulant activities of Dextran.
Chlorotrianisene Chlorotrianisene may decrease the anticoagulant activities of Dextran.
Conjugated estrogens Conjugated estrogens may decrease the anticoagulant activities of Dextran.
Mestranol The risk or severity of adverse effects can be increased when Mestranol is combined with Dextran.
Estrone sulfate Estrone sulfate may decrease the anticoagulant activities of Dextran.
Quinestrol Quinestrol may decrease the anticoagulant activities of Dextran.
Hexestrol Hexestrol may decrease the anticoagulant activities of Dextran.
Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Dextran.
Synthetic Conjugated Estrogens, B Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Dextran.
Polyestradiol phosphate Polyestradiol phosphate may decrease the anticoagulant activities of Dextran.
Esterified estrogens Esterified estrogens may decrease the anticoagulant activities of Dextran.
Zeranol Zeranol may decrease the anticoagulant activities of Dextran.
Equol Equol may decrease the anticoagulant activities of Dextran.
Methallenestril Methallenestril may decrease the anticoagulant activities of Dextran.
Epimestrol Epimestrol may decrease the anticoagulant activities of Dextran.
Moxestrol Moxestrol may decrease the anticoagulant activities of Dextran.
Estradiol acetate Estradiol acetate may decrease the anticoagulant activities of Dextran.
Estradiol benzoate Estradiol benzoate may decrease the anticoagulant activities of Dextran.
Estradiol cypionate Estradiol cypionate may decrease the anticoagulant activities of Dextran.
Estradiol valerate Estradiol valerate may decrease the anticoagulant activities of Dextran.
Biochanin A Biochanin A may decrease the anticoagulant activities of Dextran.
Formononetin Formononetin may decrease the anticoagulant activities of Dextran.
Estriol Estriol may decrease the anticoagulant activities of Dextran.
Limaprost The risk or severity of adverse effects can be increased when Limaprost is combined with Dextran.
Icosapent The risk or severity of bleeding and hemorrhage can be increased when Icosapent is combined with Dextran.
Mesalazine The risk or severity of bleeding can be increased when Mesalazine is combined with Dextran.
Indomethacin The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Dextran.
Nabumetone The risk or severity of bleeding and hemorrhage can be increased when Nabumetone is combined with Dextran.
Ketorolac The risk or severity of bleeding and hemorrhage can be increased when Ketorolac is combined with Dextran.
Tenoxicam The risk or severity of bleeding and hemorrhage can be increased when Tenoxicam is combined with Dextran.
Celecoxib The risk or severity of bleeding and hemorrhage can be increased when Celecoxib is combined with Dextran.
Tolmetin The risk or severity of bleeding and hemorrhage can be increased when Tolmetin is combined with Dextran.
Rofecoxib The risk or severity of bleeding and hemorrhage can be increased when Rofecoxib is combined with Dextran.
Piroxicam The risk or severity of bleeding and hemorrhage can be increased when Piroxicam is combined with Dextran.
Fenoprofen The risk or severity of bleeding and hemorrhage can be increased when Fenoprofen is combined with Dextran.
Valdecoxib The risk or severity of bleeding and hemorrhage can be increased when Valdecoxib is combined with Dextran.
Diclofenac The risk or severity of bleeding and hemorrhage can be increased when Diclofenac is combined with Dextran.
Sulindac The risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Dextran.
Flurbiprofen The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen is combined with Dextran.
Etodolac The risk or severity of bleeding and hemorrhage can be increased when Etodolac is combined with Dextran.
Mefenamic acid The risk or severity of bleeding and hemorrhage can be increased when Mefenamic acid is combined with Dextran.
Naproxen The risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Dextran.
Sulfasalazine The risk or severity of bleeding and hemorrhage can be increased when Sulfasalazine is combined with Dextran.
Phenylbutazone The risk or severity of bleeding and hemorrhage can be increased when Phenylbutazone is combined with Dextran.
Meloxicam The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Dextran.
Carprofen The risk or severity of bleeding and hemorrhage can be increased when Carprofen is combined with Dextran.
Diflunisal The risk or severity of bleeding and hemorrhage can be increased when Diflunisal is combined with Dextran.
Salicylic acid The risk or severity of bleeding and hemorrhage can be increased when Salicylic acid is combined with Dextran.
Meclofenamic acid The risk or severity of bleeding and hemorrhage can be increased when Meclofenamic acid is combined with Dextran.
Oxaprozin The risk or severity of bleeding and hemorrhage can be increased when Oxaprozin is combined with Dextran.
Ketoprofen The risk or severity of bleeding and hemorrhage can be increased when Ketoprofen is combined with Dextran.
Balsalazide The risk or severity of bleeding and hemorrhage can be increased when Balsalazide is combined with Dextran.
Olsalazine The risk or severity of bleeding can be increased when Olsalazine is combined with Dextran.
Lumiracoxib The risk or severity of bleeding and hemorrhage can be increased when Lumiracoxib is combined with Dextran.
Magnesium salicylate The risk or severity of bleeding and hemorrhage can be increased when Magnesium salicylate is combined with Dextran.
Salsalate The risk or severity of bleeding and hemorrhage can be increased when Salsalate is combined with Dextran.
Choline magnesium trisalicylate The risk or severity of bleeding and hemorrhage can be increased when Choline magnesium trisalicylate is combined with Dextran.
Antrafenine The risk or severity of bleeding and hemorrhage can be increased when Antrafenine is combined with Dextran.
Aminophenazone The risk or severity of bleeding and hemorrhage can be increased when Aminophenazone is combined with Dextran.
Antipyrine The risk or severity of bleeding and hemorrhage can be increased when Antipyrine is combined with Dextran.
Tiaprofenic acid The risk or severity of bleeding and hemorrhage can be increased when Tiaprofenic acid is combined with Dextran.
Etoricoxib The risk or severity of bleeding and hemorrhage can be increased when Etoricoxib is combined with Dextran.
Taxifolin The risk or severity of bleeding and hemorrhage can be increased when Taxifolin is combined with Dextran.

Referensi & Sumber

Artikel (PubMed)
  • PMID: 2435442
    Klotz U, Kroemer H: Clinical pharmacokinetic considerations in the use of plasma expanders. Clin Pharmacokinet. 1987 Feb;12(2):123-35.
  • PMID: 14864546
    RICKETTS CR: Chemistry of dextran and its derivatives. Proc R Soc Med. 1951 Jul;44(7):558-9.
  • PMID: 18572351
    Jones CI, Payne DA, Hayes PD, Naylor AR, Bell PR, Thompson MM, Goodall AH: The antithrombotic effect of dextran-40 in man is due to enhanced fibrinolysis in vivo. J Vasc Surg. 2008 Sep;48(3):715-22. doi: 10.1016/j.jvs.2008.04.008. Epub 2008 Jun 24.
Textbook
  • Gray A., Wright J., Goodey V. and Bruce L. (2011). Injectable drugs guide. Royal pharmaceutical society .
  • Collins P. (2006). Dictionary of carbohydrates (2nd ed.). Taylor and Francis.

Contoh Produk & Brand

Produk: 124 • International brands: 0
Produk
  • 10% Dextran 40 In 0.9% Sodium Chloride Injection
    Solution • - • Intravenous • Canada • Approved
  • 10% Dextran 40 In 5% Dextrose Injection
    Solution • - • Intravenous • Canada • Approved
  • 6% Dextran 70 In 0.9% Sodium Chloride Injection
    Solution • - • Intravenous • Canada • Approved
  • Advance Relief Eye Drops
    Solution / drops • - • Ophthalmic • US • OTC
  • Advanced relief
    Liquid • - • Ophthalmic • US • OTC
  • Advanced Relief
    Liquid • - • Ophthalmic • US • OTC
  • Advanced relief
    Liquid • - • Ophthalmic • US • OTC
  • Advanced Relief Eye Drops
    Solution • - • Ophthalmic • Canada • OTC • Approved
Menampilkan 8 dari 124 produk.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul